Exiqon Diagnostics announced that it now offers KRAS Mutation Analysis
through its CLIA laboratory in California. Cancer treating physicians now have
access to this critical test for their advanced stage colorectal and non-small
cell lung cancer patients who are candidates for anti-EGFR therapy. In the
United States, there are approximately 150,000 new colorectal cancer cases and
over 200,000 lung cancer cases diagnosed each year.1) Many of these patients may
present with advanced disease.
In those cases, confirmed KRAS mutation status
is important information for physicians to have when deciding on a treatment
regimen that may contain EGFR-targeted therapies. Published clinical studies
demonstrate that KRAS gene mutations are associated with poor prognosis and
lack of response to EGFR inhibitor therapies.

Recent studies strongly correlate the presence of KRAS mutations in colorectal
cancer patients with lack of response to cetuximab and panitumumab, shorter
progression-free survival (PFS) and shorter overall survival. Studies performed
in NSCLC have shown that mutations in the KRAS gene are strongly predictive of
resistance to tyrosine kinase inhibitors such as gefitinib and eroltinib.

KRAS mutation testing is recommended by the National Comprehensive Cancer
Network (NCCN) before starting EGFR-targeted therapy in both metastatic
colorectal cancer and advanced non-small cell lung cancer patients.2,3).
The American Society of Clinical Oncology (ASCO) favors routine KRAS
mutation testing for patients diagnosed with metastatic colorectal cancer
before initiating anti-EGFR therapies.

“The ability to determine patient response to a particular therapy before it is
administered is critical to prioritizing from an ever increasing list of
potential treatment options”, said Doug Harrington, M.D., Medical Director,
Exiqon Diagnostics. “KRAS Mutation Analysis is an important new diagnostic that
is now available to help physicians stratify their advanced stage colorectal or
non-small cell cancer patients as appropriate candidates for treatment with
EGFR inhibitors. Those patients who have the mutation would most likely not
respond to anti-EGFR drugs and should not be treated with those ineffective and
expensive agents.”

KRAS Mutation Analysis is a welcome addition to the growing molecular
diagnostics test menu available at Exiqon Diagnostics. Additional targeted
molecular profiling assays are currently in development and will be launched
later this year to help physicians more effectively guide treatment decisions.
KRAS testing is just one of the many molecular biomarkers that will be
available to help physicians personalize therapeutic treatment plans.

References

1. American Cancer Society: Cancer Facts and Figures 2008
2. NCCN Clinical Practice Guidelines in Oncology™ Colon cancer. v 2.2009.
Available at: http://www.nccn.org
3. NCCN Clinical Practice Guidelines in Oncology™ Non-small cell lung cancer. v
2.2009. Available at: http://www.nccn.org

Source
Exiqon Diagnostics

NHS Smoking Service says one in two smokers will die from their habit. NHS Somerset is urging people to protect themselves against lung cancer as part of national Cancer Prevention Week. Smoking is the biggest single risk factor: in the UK approximately one third of all cancer deaths are attributable to smoking. According to the South West Public Health Observatory, the poorest fifth of the population has double the rate of lung cancer than the richest.

While the rates have been steady for the richest women with lung cancer, they have gone up by 30 per cent for the poorest women. Death rates in the poorest women have also gone up by 18 per cent over the last 20 years.

One in two smokers dies prematurely and nearly one in four will die of lung cancer.

Current smokers are fifteen times more likely to die from lung cancer than life-long non-smokers.

Jonathan Chetland from Somerset NHS Stop Smoking Service said: “Smoking is the single biggest contributor to health inequalities, premature death and disease in the UK. More than one in two of all lifelong smokers will die from their habit through diseases such as lung cancer”.

“70 per cent of smokers want to quit. Many smokers have tried to unsuccessfully quit on their own and have been put off trying again. The NHS Stop Smoking Service provides a wide range of advice and support.

Give the service a call and talk to a friendly advisor who can help you on the road to a smoke-free life on 0844 568 9840 or visit http://www.somersetstopsmoking.nhs.uk

Source
NHS Somerset

People who live in urban areas are more likely to develop late-stage cancer than those who live in suburban and rural areas. That is the conclusion of a new study published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study’s results indicate a need for more effective urban-based cancer screening and awareness programs.

Diagnosing cancer at an early stage can improve outcomes. Studies show certain groups, such as low income populations, are more likely to be diagnosed with cancer at later stages. While some studies have also found that geography can affect the timing of cancer diagnoses, research on rural-urban disparities has produced mixed and conflicting findings.

To investigate the rural and urban differences in late-stage cancer diagnoses, Sara L. McLafferty, Ph.D., of the University of Illinois and Fahui Wang, Ph.D., of Louisiana Sate University analyzed data from the Illinois State Cancer Registry from 1998 to 2002. The investigators noted that Illinois is an appropriate area to study because it encompasses a diverse range of geographic regions from the densely populated Chicago metropolitan area to low-density, remote rural areas. They assessed late-stage cancer diagnoses of the four major types of cancer (breast, colorectal, lung, and prostate) throughout the state, comparing data from cities with those from less-populated regions.

The researchers found that for all four cancers, risk was highest in the most highly urbanized area (Chicago) and decreased as areas became more rural. However, in the most isolated rural areas, risk was also high. Risks were considerably low among patients living in large towns in rural areas.

For colorectal and prostate cancers, and to a lesser extent breast cancer, these disparities stemmed mainly from differences in the ages and races of individuals in the various geographic areas. A high concentration of vulnerable populations and economically disadvantaged areas in Chicago and its suburbs accounted for the high rates of late-stage diagnosis found in these highly urban areas. Among the different races, the black population was particularly vulnerable to late diagnosis. In contrast, the lower rates of late-stage diagnosis in rural areas reflected the greater presence of elderly patients who have a lower risk of late-stage diagnosis, likely because of frequent doctors’ visits and age-related cancer screenings.

Differences in age and race did not explain the geographic disparities seen for lung cancer, indicating that other factors-such as cancer awareness or diagnostic differences-account for the rural-urban differences in late-stage lung cancer diagnosis.

The authors conclude that their study found a reversal of the commonly held view that late-stage cancer risks are highest for rural residents. “The concentration of health disadvantage in highly urbanized places emphasizes the need for more extensive urban-based cancer screening and education programs, especially programs targeted to the most vulnerable urban populations and neighborhoods,” they write.

Article: “Rural reversal? Rural-urban disparities in late-stage cancer risk in Illinois.”
Sara McLafferty, Fahui Wang.
CANCER; Published Online: May 11, 2009 (DOI 10.1002/cncr.24315); Print Issue Date: June 15, 2009.

Source
American Cancer Society


Warning: chmod() [function.chmod]: Operation not permitted in /usr/local/lib/php/httpcache-class.php on line 50
| Copyright 2009 |
online pharmacy ambien no prescription buy xanax online no prescription online tramadol buying xanax online buy soma